Drugs / LY3143921
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03096054 | Jun 2017 → Apr 2025 | colorectal cancer, head and neck squamous cell carcinoma, malignant ovarian serous tumor, malignant pancreatic neoplasm +3 | Cancer Research UK | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3143921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03096054 ↗ |
| Known as | LY-3143921 MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068779 ↗ |
| Known as | LY3143921 hydrate | “This clinical study looked at a drug called LY3143921 hydrate, which is a Cdc7 inhibitor.” NCT03096054 ↗ |
| Action | Inhibit | “would block the function of Cdc7” NCT03096054 ↗ |
| Modality | Small molecule | “a Cdc7 inhibitor” NCT03096054 ↗ |
| Route | Oral | “LY3143921 hydrate was administered orally on a daily schedule.” NCT03096054 ↗ |
| Target | CDC7 | “a Cdc7 inhibitor” NCT03096054 ↗ |